TCRX shifts focus to in vivo TCR-T solid tumor programs
TCRX says a reorganization will advance two in vivo TCR-T solid tumor candidates to IND-enabling studies and plan Phase 1 trials in late 2027, while pausing or seeking partners for heme malignancy and autoimmune programs.
A major reorganization shifts focus to in vivo TCR-T therapies for solid tumors, advancing two candidates to IND-enabling studies and planning Phase 1 trials in late 2027.
Heme malignancy and autoimmune programs are paused or seeking partners, with $55 million in cost savings expected.Original docu…